Tumor News and Research

RSS

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.

26 Aug 2015

Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center.

26 Aug 2015

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery.

25 Aug 2015

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.

25 Aug 2015

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer.

25 Aug 2015

Mayo Clinic scientists discover potential way to reprogram cancer cells back to normalcy

Cancer researchers dream of the day they can force tumor cells to morph back to the normal cells they once were. Now, researchers on Mayo Clinic's Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.

25 Aug 2015

Karolinska Institutet study may lead to development of better immune-based cancer therapies

A study by researchers at Sweden's Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells. The results, which are being published in the 'Journal of the National Cancer Institute', can contribute to the development of better immune-based cancer therapies.

25 Aug 2015

Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma Inc. reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells.

24 Aug 2015

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers.

24 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.

23 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

New set of genes can indicate improved survival after surgery for pancreatic cancer patients

A study by the Translational Genomics Research Institute and other major research institutes, found a new set of genes that can indicate improved survival after surgery for patients with pancreatic cancer. The study also showed that detection of circulating tumor DNA in the blood could provide an early indication of tumor recurrence.

21 Aug 2015

Researchers establish structure of important tumor-suppressing protein

An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN. Their findings provide new insights into how the protein regulates cell growth and how mutations in the gene that encodes the protein can lead to cancer.

21 Aug 2015

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge."

20 Aug 2015

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

DelMar closes on $2.6 million registered direct placement

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced the closing of a registered direct placement (Placement) with $2.6 million received from the offering.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,789 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Tumor News and Research

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

New research finds five different types of prostate cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Mayo Clinic scientists discover potential way to reprogram cancer cells back to normalcy

Karolinska Institutet study may lead to development of better immune-based cancer therapies

Regen BioPharma implements gene silencing technology in killing cancer stem cells

Beta-blockers improve overall survival among epithelial ovarian cancer patients

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

New set of genes can indicate improved survival after surgery for pancreatic cancer patients

Researchers establish structure of important tumor-suppressing protein

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

DelMar closes on $2.6 million registered direct placement

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News